Rationality of the FIGO2023 staging for early-stage endometrial cancer,compared with the FIGO2009 staging  

作　　者：Aoxuan Zhu Yangyang Dong Xingchen Li Yiqin Wang Jianliu Wang 

机构地区：[1]PekingUniversity People's Hospital,Beijing,China

出　　处：《Gynecology and Obstetrics Clinical Medicine》2024年第1期11-20,共10页妇产科临床医学（英文）

基　　金：National Key Research and Development Program of China(2022YFC2704405).

摘　　要：Objective The International Federation of Gynecology and Obstetrics(FIGO)released a new stagingfor endometrial cancer(EC),which revised the FIG02009 staging to include histopathological andmolecular features.The purpose of this study was to validate the prognostic accuracy of the new staging and discuss its clinical applicability.Methods In this single-centre retrospective study,540 patients with primary surgically treated early-stage EC were enrolled and staged according to FIG02009/2023.Kaplan-Meier survival analysis was used to compare for prognostic differentiation.Cox regression was used to identify potential prognostic indicators.Results A total of 81 patients underwent staging shifts,allstage elevation.The prognosis difference between new stages I and Il was more significant.The new staging was more predictive of death postoperatively.Lesion maximum diameter(LMD)was one of the independent risk factors associated with prognosis.Taking LMD=5.70 cm as the cut-off value could further differentiate patients with divergent prognoseswithin FIG02023stage IIC.Conclusion FIG02023 stagingdemonstrated greater prognostic accuracy.In addition,LMD may be another critical factor affecting prognosis.

关 键 词：STAGING CANCER ENDOMETRIAL 

分 类 号：R737.33[医药卫生—肿瘤]